Common cold infection may train the body to recognise coronavirus: Study

The immune system's memory helper T cells also identifies some parts of the novel coronavirus, according to a study whose findings may explain why some people have milder Covid-19 cases than others.

coronavirus, coronavirus vaccine
Press Trust of India Los Angeles
3 min read Last Updated : Aug 05 2020 | 3:02 PM IST

The immune system's memory helper T cells which recognise the common cold virus and help the body fight it off, also identifies some parts of the novel coronavirus, according to a study whose findings may explain why some people have milder COVID-19 cases than others.

The research, published in the journal Science, noted that the immune system's memory T cells keep track of the viruses they have seen before, giving the cells a headstart in recognising and fighting off repeat invaders.

However, the scientists, including those from La Jolla Institute (LJI) in the US, cautioned that it is too soon to say whether such pre-existing immune cell memory affects COVID-19 clinical outcomes.

"We have now proven that, in some people, pre-existing T cell memory against common cold coronaviruses can cross-recognise SARS-CoV-2, down to the exact molecular structures," said Daniela Weiskopf, a co-author of the study from LJI.

"This could help explain why some people show milder symptoms of disease while others get severely sick," Weiskopf said.

Alessandro Sette, another co-author of the study from LJI, noted that the reactivity of the immune system may translate to different degrees of protection.

"Having a strong T cell response, or a better T cell response may give you the opportunity to mount a much quicker and stronger response," Sette said.

An earlier study by Sette and his team had shown that 40 to 60 per cent of people who were never exposed to the novel coronavirus SARS-CoV-2 had T cells that reacted to the virus.

According to the study, the immune systems in these individuals recognised fragments of the virus it had never seen before -- a finding which was also reported among people in the Netherlands, Germany, Singapore, and the UK.

In the current research, the scientists assessed samples collected from study participants who had never been exposed to SARS-CoV-2.

They defined the exact parts of the virus that are responsible for the cross-reactive T cell response.

Their analysis showed that unexposed individuals can produce a range of memory T cells that are equally reactive against SARS-CoV-2, and four types of common cold coronaviruses.

Based on the finding, the scientists said fighting off a common cold coronavirus could teach the T cell compartment to recognise some parts of SARS-CoV-2 as well.

They believe this process provides evidence for the hypothesis that common cold viruses can, in fact, induce cross-reactive T cell memory against SARS-CoV-2.

"We knew there was pre-existing reactivity, and this study provides very strong direct molecular evidence that memory T cells can 'see' sequences that are very similar between common cold coronaviruses and SARS-CoV-2," Sette said.

The scientists found that while some cross-reactive T cells targeted the SARS-CoV-2's spike protein -- the region of the virus that recognises and binds to human cells -- pre-existing immune memory was also directed to other SARS-CoV-2 proteins.

Sette noted that the finding is relevant since most vaccine candidates target the spike protein.

The findings, according to the researchers, suggest the hypothesis that inclusion of additional SARS-CoV-2 targets might enhance the potential to take advantage of this cross reactivity, and could further enhance vaccine potency.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirusdisease

First Published: Aug 05 2020 | 2:49 PM IST

Next Story